Blueprint Medicines所有资讯

Blueprint Medicines | 144：拟议出售证券

11/28 07:53

Blueprint Medicines | 4：持股变动声明-董事 COATS LONNEL

11/23 05:51

Blueprint Medicines | 144：拟议出售证券

11/22 05:25

Blueprint Medicines | 144：拟议出售证券

11/21 05:33

Blueprint Medicines | SC 13G/A：超过5%持股股东披露文件(修正)-T. ROWE PRICE ASSOCIATES, INC.(8.5%)

11/15 02:29

Blueprint Medicines | 4：持股变动声明-董事 Albers Jeffrey W.

11/13 05:21

Blueprint Medicines | 144/A：其他

11/13 02:48

Blueprint Medicines | 144：拟议出售证券

11/08 06:33

Blueprint Medicines | 10-Q：2024财年三季报

10/31 04:32

Blueprint Medicines | 8-K：Blueprint Medicinib 公布2024年第三季度业绩并上调了AYVAKIT® /AyvaKYT®（avapritinib）全年收入指引

10/30 19:11

Blueprint Medicines | 4：持股变动声明-高管 Namouni Fouad

10/05 05:14

Blueprint Medicines | 4：持股变动声明-董事 Albers Jeffrey W.

09/12 04:11

Blueprint Medicines | 144：拟议出售证券

09/10 09:26

Blueprint Medicines | 4：持股变动声明-高管 Landsittel Michael

08/20 04:03

Blueprint Medicines | 144：拟议出售证券

08/16 04:32

Blueprint Medicines | 4：持股变动声明-高管 Lee Philina

08/08 05:12

Blueprint Medicines | 144：拟议出售证券

08/06 04:53

Blueprint Medicines | 10-Q：2024财年二季报

08/02 04:52

Blueprint Medicines | 8-K：Blueprint Medicinib 公布2024年第二季度业绩并上调了AYVAKIT® /AYVAKYT®（avapritinib）全年收入指引

08/01 19:31

Blueprint Medicines | 4：持股变动声明-高管 Carter Percy H.

07/09 07:13